IPO Timeline Raw facts
Company Overview
| Stock Name | 160 Health |
|---|---|
| Stock Code | 02656 |
| Company Full Name | 160 Health International Limited |
| Industry | Healthcare |
| Principal Activities | We are an experienced Chinese wholesaler of pharmaceutical and health products and a leading integrated digital healthcare service provider. We provide customers with a variety of pharmaceutical and health products, as well as comprehensive digital healthcare solutions. Under our wholesale and retail model, we offer a range of high-quality pharmaceutical and health products to meet the diverse needs of our customers. In addition, we also provide digital healthcare solutions through our online healthcare service platform, the Health 160 platform, empowering various platform participants across the entire healthcare industry chain (mainly including enterprise customers, healthcare institutions, medical and nursing personnel, individual users and third-party merchants), and promoting the digital transformation of China’s healthcare industry. |
| Listing Date | 2025-09-17 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 深圳市 南山區 南山街道 東濱路4078號 永新時代廣場 2號樓9層、11至12層 |
| Business Address (Hong Kong) | 香港 銅鑼灣 勿地臣街1號 時代廣場 二座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.91160.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 11.89 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 250 shares |
| Entry Threshold | HK$ 2,972 |
| Par Value | RMB 2e-06 / shares |
| Offer Period | 2025-09-09 to 2025-09-12 |
| Global Offering Shares | 33,645,500 shares |
| HK Public Offer Shares (Initial) | 3,364,750 shares (10.0%) |
| Public Offer Lots (Initial) | 13,459lots (Pool A6,729lots,Pool B6,730lots) |
| International Placing Shares (Initial) | 30,280,750 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 336,452,810 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | SHENWAN HONGYUAN CAPITAL (H.K.) LIMITED CE ABC209 |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 400,044,995 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 250 | HK$ 2,972 |
| 2 lots | 500 | HK$ 5,945 |
| 3 lots | 750 | HK$ 8,918 |
| 4 lots | 1,000 | HK$ 11,890 |
| 5 lots | 1,250 | HK$ 14,862 |
| 6 lots | 1,500 | HK$ 17,835 |
| 7 lots | 1,750 | HK$ 20,808 |
| 8 lots | 2,000 | HK$ 23,780 |
| 9 lots | 2,250 | HK$ 26,752 |
| 10 lots | 2,500 | HK$ 29,725 |
| 20 lots | 5,000 | HK$ 59,450 |
| 30 lots | 7,500 | HK$ 89,175 |
| 40 lots | 10,000 | HK$ 118,900 |
| 50 lots | 12,500 | HK$ 148,625 |
| 60 lots | 15,000 | HK$ 178,350 |
| 70 lots | 17,500 | HK$ 208,075 |
| 80 lots | 20,000 | HK$ 237,800 |
| 90 lots | 22,500 | HK$ 267,525 |
| 100 lots | 25,000 | HK$ 297,250 |
| 120 lots | 30,000 | HK$ 356,700 |
| 140 lots | 35,000 | HK$ 416,150 |
| 160 lots | 40,000 | HK$ 475,600 |
| 180 lots | 45,000 | HK$ 535,050 |
| 200 lots | 50,000 | HK$ 594,500 |
| 240 lots | 60,000 | HK$ 713,400 |
| 280 lots | 70,000 | HK$ 832,300 |
| 320 lots | 80,000 | HK$ 951,200 |
| 360 lots | 90,000 | HK$ 1,070,100 |
| 400 lots | 100,000 | HK$ 1,189,000 |
| 600 lots | 150,000 | HK$ 1,783,500 |
| 800 lots | 200,000 | HK$ 2,378,000 |
| 1,000 lots | 250,000 | HK$ 2,972,500 |
| 1,200 lots | 300,000 | HK$ 3,567,000 |
| 1,600 lots | 400,000 | HK$ 4,756,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 500,000 | HK$ 5,945,000 |
| 2,400 lots | 600,000 | HK$ 7,134,000 |
| 3,200 lots | 800,000 | HK$ 9,512,000 |
| 4,000 lots | 1,000,000 | HK$ 11,890,000 |
| 4,800 lots | 1,200,000 | HK$ 14,268,000 |
| 6,729 lots | 1,682,250 | HK$ 20,001,952 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 9.98B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 4,498,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 108.2 million (2024) |
| Period-End Cash Balance | RMB 37.7 million |
| Listing Expenses | ~HK$ 86,400,000 |
| Listing Expenses / Funds Raised | ~19.2% |
| Total Pre-IPO Investment | RMB 733.4 million |
| First Day Close | HK$ 28.22 |
|---|---|
| First Day Open | HK$ 29.98 |
| First Day Change | 137.34% |
| First Day Volume | 7081940.0 |
| First Day Turnover | 199579000.0 |
| Use of Proceeds | 1、約40.0%(或145.3百萬港元)將用于進一步擴大醫療資源覆蓋面,增加平臺流量;
2、約30.0%(或109.1百萬港元)將用于加強研發能力;
3、約10.0%(或36.4百萬港元)將用于豐富產品及服務種類并探索增值服務;
4、約10.0%(或36.4百萬港元)將用于有選擇地進行戰略合作及收購;
5、約10.0%(或36.4百萬港元)將用作營運資金及一般企業用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
天元律师事务所(有限法律责任合伙) 上海澄明则正律师事务所 Harney Westwood & Riegels |
| Legal Advisor to Sponsors/Underwriters |
欧华律师事务所 汉坤律师事务所 竞天公诚律师事务所 |
| Auditor and Reporting Accountant | 罗兵咸永道会计师事务所 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Receiving Banks | 招商永隆银行 |
Cornerstone Investors
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 羅寧政 | — |
| Company Secretary | 唐世華 | — |
| Executive Director | 罗宁政 | LUO Ningzheng |
| Non-Executive Director | 张如协 | ZHANG Ruxie |
| Independent Non-Executive Director | 邹钧 | ZOU Jun |
| Executive Director | 冀翠琳 | JI Cuilin |
| Non-Executive Director | 孙萌 | SUN Meng |
| Independent Non-Executive Director | 徐卫国 | XU Weiguo |
| Executive Director | 黄浪 | HUANG Lang |
| Independent Non-Executive Director | 范明 | FAN Ming |
| Executive Director | 王立法 | WANG Lifa |
Major Shareholders
| Major Shareholders & Holdings | Mr. Luo holds 102,912,905 shares (representing 30.59%) through Luo Holdings Limited and controls approximately 3.49% of the voting rights through a voting agreement. 傅哲寬 is deemed to have an interest in 51,701,065 shares (representing 15.37%), including entities controlled through 啟賦基金 and LFL Limited held by his spouse 林芳荔. 啟賦私募基金管理有限公司 holds 43,688,810 shares (representing 12.99%). |
|---|
Market Sentiment
健康160录得751.77倍超额认购,市场申购热情极为高涨,反映出医疗健康板块的强劲吸引力。一手(250股)中签率仅12.72%,竞争激烈程度远超近年平均水平;最终发售价11.89港元,在炽热需求下或已按区间上限定价。
Tier Analysis
甲尾(300手)期望中签仅0.29手,而乙头(400手)可稳获1手,档位效率显著倒挂,甲组资金利用率偏低。若考虑乙组获取分配所需股数门槛及中签手数,乙头较甲尾呈现出更优的成本效益,但不同券商手续费结构各异,实际成本可能不同。
Demographics
此次分配数据未提供合格申购人的人口画像明细,中国内地及香港参与比例均显示为0,可能因数据源未完整披露,无法进行地域集中度分析。投资者应以港交所后续发布的详尽权益披露公告为准。




